Trevi Therapeutics (TRVI) Tops Q4 EPS by 2c

Trevi Therapeutics (NASDAQ: TRVI) reported Q4 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Smith-Midland Corporation (SMID) Tops Q2 EPS by 26c
• The LGL Group (LGL) Misses Q2 EPS by 8c